X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EQ001 (itolizumab) is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells. It is being evaluated for the treatment of Lupus Nephritis.
Lead Product(s): Itolizumab
Therapeutic Area: Nephrology Product Name: EQ001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
EQ302 is an orally delivered stapled peptide inhibitor of IL-15 and IL-21 derived from EQ102. It is being evaluated in pre-clinical studies for the treatment of gastrointestinal diseases.
Lead Product(s): EQ302
Therapeutic Area: Gastroenterology Product Name: EQ302
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
EQ001 (itolizumab) is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
MET642, a potent, sustained, non-bile acid farnesoid x-receptor (FXR) agonist, is a non-immunosuppressive treatment for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Lead Product(s): MET642
Therapeutic Area: Gastroenterology Product Name: MET642
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Metacrine
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Termination December 23, 2022
Details:
Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $164.5 million Upfront Cash: $26.0 million
Deal Type: Agreement December 06, 2022
Details:
EQ101, a first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, and EQ102, a first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21. EQ101 will be administered intravenously once weekly over 24 weeks at a dose level of 2 mg/kg.
Lead Product(s): EQ101
Therapeutic Area: Dermatology Product Name: EQ101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
EQ102 is a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21, has demonstrated the prevention of intestinal tissue damage in a humanized mouse model of gastrointestinal inflammation.
Lead Product(s): EQ102
Therapeutic Area: Gastroenterology Product Name: EQ102
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
EQ001 (itolizumab), a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Lead Product(s): Itolizumab,EQ101
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
EQ001 (itolizumab) is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.
Lead Product(s): Itolizumab
Therapeutic Area: Nephrology Product Name: EQ001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
Through the acquisition, Equillium adds Metacrine’s farnesoid X receptor platform, including lead molecule MET642, an orally delivered FXR agonist that is a non-immunosuppressive treatment for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Lead Product(s): MET642
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET642
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Metacrine
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
